Who Paid My Doc Search
Menu
Organisation paid for research Program year 2024 Source: CMS Open Payments

San Marcus Research Clinic

Neither a doctor nor a teaching hospital

Research payments

$1,600,163

632 payments

Through program year 2024, San Marcus Research Clinic is reported as receiving $1,600,163 in research payments, across 632 payments.

By program year

6 rows
Year Kind Amount Payments
2024 Research $10,209 19
2023 Research $101,644 27
2022 Research $128,362 7
2021 Research $213,958 108
2020 Research $270,651 170
2019 Research $875,339 301

Breakdown

Who paid Research payments · program years 2019–2024
  1. Bayer HealthCare Pharmaceuticals Inc. $1,033,800 420 payments
  2. E.R. Squibb & Sons, L.L.C. $212,951 8 payments
  3. Vifor (International) Ltd. $101,228 94 payments
  4. Mallinckrodt Enterprises LLC $101,033 7 payments
  5. Endo Pharmaceuticals Inc. $82,715 12 payments
  6. Kiniksa Pharmaceuticals, Ltd. $30,157 49 payments
  7. Boehringer Ingelheim Pharmaceuticals, Inc. $18,349 2 payments
  8. Kiniksa Pharmaceuticals International, plc $10,209 19 payments
  9. Alexion Pharmaceuticals, Inc. $5,000 1 payment
  10. Boehringer Ingelheim RCV GmbH & Co KG $4,491 18 payments
Studies the money was for Research payments · program years 2019–2024
  1. BAY94-8862 ph 3 conventional in diabetic nephropathy $873,325 366 payments
  2. BAY 94-8862 ph 3 conventional in diab nephropathy $160,475 54 payments
  3. Diamond Pat-Cr-302 $101,228 94 payments
  4. An Open-Label, Randomized, Parallel-Group, Three Treatment Arm, Multicenter Study on Hypogonadal Males to Evaluate the Effect on 24-Hour Ambulatory Blood Pressure After 16-Week Continuous Treatment with Marketed Testosterone Products $82,715 12 payments
  5. A Multicenter 2-Part Study to Assess the Safety and Efficacy of H.P. Acthar Gel in Subjects With Rheumatoid Arthritis and Moderate to Severe Disease Activity Despite Dual-Dmard Treatment $55,959 2 payments
  6. Phase II Umbrella AD $51,903 1 payment
  7. Phase II Umbrella AD - A Phase 2, Randomized, Double-blinded, Placebo-controlled, 5 Parallel-group Study of BMS-986166 or Branebrutinib for the Treatment of Patients with Moderate to Severe Atopic Dermatitis $49,301 1 payment
  8. A Multicenter, Randomized, Placebo Controlled Study to Assess the Efficacy and Safety of H.P. Acthar Gel in Subjects With Persistently Active Systemic Lupus Erythematosus Despite Moderate Dose Corticosteroids $45,074 5 payments
  9. A Phase 2, Multicenter, Randomized, Double-blind, Placebo Controlled Study to Assess the Safety, Pharmacokinetics, and Efficacy of KPL-404 in Subjects With Moderate to Severe Active Rheumatoid Arthritis With Inadequate Response or Intolerance to at Least One Biologic Disease-modifying Anti-rheumatic Drug or a Janus Kinase Inhibitor $36,157 36 payments
  10. Phase II Umbrella Study - A Phase 2, Randomized, Double-blinded, Placebo-controlled, 5 Parallel-group Study of BMS-986166 or Branebrutinib for the Treatment of Patients with Moderate to Severe Atopic Dermatitis $30,988 1 payment

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2024

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record